The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
RCO2R' + NH2R″ → RCONHR″ + R'OH This reaction is not usually reversible. Hydrazines and hydroxylamine can be used in place of amines. Esters can be converted to isocyanates through intermediate hydroxamic acids in the Lossen rearrangement. Sources of carbon nucleophiles, e.g., Grignard reagents and organolithium compounds, add readily to the carbonyl.
The interaction between fibronectin and the integrin receptor causes a conformational change in the fibronectin. Additional receptors bind to fibronectin bringing in type I collagen, procollagen I and collagen V. These molecules interact with fibronectin to promote fibril formation on the surface of the cell.
Acetylcholinesterase collagenic tail peptide also known as AChE Q subunit, acetylcholinesterase-associated collagen, or ColQ is the collagen-tail subunit of acetylcholinesterase found in the neuromuscular junction. In humans it is encoded by the COLQ gene.
Sources: en.wikipedia.org
In 1912, Liu went to Beijing to continue his education, attending the Beijing Army Middle School and graduating in 1914. He later studied at the Baoding Military Academy, graduating in 1916 or 1917. During this time, Liu was influenced by Jiang Baili, the president of the academy and a prominent military instructor and theorist. Jiang's lessons were supposedly extremely patriotic and nationalistic in nature, to the point where he choked back tears during lectures recounting the various humiliations China had suffered.
== Contraindications == Mohs surgery is generally contraindicated when the criteria summarized in the “Uses” section above are not met. For example, the tumor is small, low-risk, has well-defined margins, and is in a non-critical area. The standard protocol for Mohs surgery requires the surgeon to both remove the tissue and interpret the pathology. The procedure is not considered Mohs surgery if the removed tissue is sent and read by a pathologist instead of the surgeon performing the procedure. In this case, it is considered a standard excision and should be documented as such. Another doctor interpreting histopathology is incompatible with Mohs surgery. Relative contraindications include instances where the risks of surgery outweigh the benefits such as in patients with co-morbidities, in cases where the defect caused by surgery would need complex reconstruction beyond the scope of the surgery, or when patient factors such as severe bleeding predispositions or being unable to tolerate local anesthesia would affect the prognosis. Increased postoperative complications are associated with immunosuppressed patients (e.g. solid organ transplant recipients) and elderly patients. These are not absolute contraindications, but the risks of this procedure should be weighed against the benefits for each individual patient.
=== 1989 === January 7, 1989 – Japanese Emperor Hirohito dies, he was succeeded by his son Akihito. January 20, 1989 – George H. W. Bush becomes president of the United States. February 1989 – End of Soviet–Afghan War; continuation of internal conflict without Soviet troops. June 3, 1989 – Iranian leader Ayatollah Khomeini dies. June 4, 1989 – Tiananmen Square protests of 1989 in Beijing, People's Republic of China. June 4, 1989 – Solidarity's decisive victory in the first partially free parliamentary elections in post-war Poland sparks off a succession of anti-communist Revolutions of 1989 across Central, later South-East and Eastern Europe. August 14, 1989 – South African president Pieter Willem Botha resigns in reaction to the implementation of Tripartite Accord. August 19, 1989 – The opening of the border gate between Austria and Hungary at the Pan-European Picnic set in motion a chain reaction, at the end of which there was no longer a GDR and the Eastern Bloc had disintegrated. August 23, 1989 – Soviet Politburo member Alexander Yakovlev denounces the secret protocols of the Hitler-Stalin Pact. August 24, 1989 – Tadeusz Mazowiecki becomes the prime minister of Poland forming the first non-communist government in the Communist bloc. October 23, 1989 – End of Communism in Hungary. November 9, 1989 – Fall of the Berlin Wall. November 24, 1989 – Communist Party of Czechoslovakia leaders resign during the Velvet Revolution, effectively ending one-party rule in that country.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.